- Symptomatic treatment of insomnia should be initiated only after careful evaluation of the patients, as sleep disturbances may be the presenting feature of a physical and/or psychiatric disorder. Failure of insomnia to remit after 7-10 days of therapy may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated
- Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder
- Use the lowest effective dose in the elderly patients because the important adverse events of quazepam are dose related
- Complex behaviors including sleep-driving, preparing and eating food, making phone calls, or having sex may occur with sedative-hypnotics at therapeutic doses. Concomitant use of alcohol and other CNS depressants may increase the risk of such behaviors; discontinue the drug if such events occur
- Angioedema involving the tongue, glottis or larynx, and additional adverse events such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis may occur after taking the first or subsequent doses of quazepam and could be fatal; do not re-administer the drug in patients who develop angioedema after treatment
- Patients should avoid engaging in hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery during therapy, because of its potent CNS depressant effects
- Withdrawal signs and symptoms may occur following rapid reduction or abrupt discontinuation. If the treatment is to be discontinued or the dose reduced after prolonged therapy, gradually taper the dose
- Use the lowest effective dose in elderly and/or debilitated patients
Cautions: Use cautiously in
- Hepatic impairment
- Renal impairment
- History of alcohol or drug abuse
- Pulmonary impairment
- Depression
- Alcohol use
- Seizure disorder
Pregnancy Category:X
Breastfeeding: No information is available on the long-term use of quazepam during breastfeeding. Since quazepam and its metabolites could accumulate in the breastfed infant, an alternate drug may be preferred while nursing a newborn or preterm infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 11 May 2011). As per manufacturer's data, because quazepam and its metabolites are excreted in the breast milk, it is not recommended for use in nursing women.
Pricing data from www.DrugStore.com in U.S.A.
- Doral 7.5 MG TABS [Bottle] (MEDA PHARMACEUTICALS)
30 mg = $100.98
90 mg = $290.97 - Doral 15 MG TABS [Bottle] (QUESTCOR)
30 mg = $127.99
90 mg = $369.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
